BASIC PROGRAM CONTENT Sample Clauses

BASIC PROGRAM CONTENT. Contractor shall provide: • One (1) Communications Satellite (ICO 2 GHz GEO) in accordance with Exhibit B (Satellite Performance Specification), and tested in accordance with Exhibit D (Satellite Test Plan). This Satellite shall be delivered to a designated Launch Site as specified in the Contract. Contractor shall conduct a Product Assurance program in accordance with Exhibit C (Product Assurance Program Plan). Contractor shall be responsible for shipping the Satellite to the Launch Site. • Necessary ground support equipment to permit full checkout and test of the Satellite during acceptance testing and pre-Launch operations. • Necessary support to the GBBF provider as defined further in paragraph 2.3.11 (Ground Based Beam Forming Support) • Classroom training to Purchaser on the Satellite to familiarize experienced operations personnel with the systems and subsystems, and operations of the Satellite as specified in paragraph 2.3.3 (Training of Purchaser Personnel) of this SOW. • The support personnel for pre-Launch activities and Launch Support Services. • Tracking, Telemetry, and Command (TT&C) ground stations capability during transfer orbit. • Mission Operations Services from Satellite separation from the Launch Vehicle through completion of IOT (except as noted in paragraph 2.4 of this SOW). During this period, all Mission Operations shall be performed/controlled from Contractor’s Mission Control Center (MCC). • Data as specified in the Contract Data Requirements List (CDRL), Annex 1 attached to this SOW.
Sample 1
AutoNDA by SimpleDocs
BASIC PROGRAM CONTENT. Contractor shall provide: • One (1) Space Segment in accordance with the Space Segment Performance Specification, Exhibit E, and tested in accordance with the Space Segment Program Test Plan, Exhibit H. Contractor shall conduct a Product Assurance program in accordance with the Product Assurance Plan, Exhibit C. • The Space Segment delivery shall include the delivery of a Ground Based Beam Forming Subsystem, including: [*] • SSIOT. • Concerning the development, delivery, and acceptance of the GBBF Subsystem, the Contractor shall conduct a Product Assurance program in accordance with the GBBF Subsystem Quality Assurance Plan, CDRL 27. • Necessary ground support equipment to permit full checkout and test of the GBBF Subsystem during AT. • Necessary ground support equipment to permit full checkout and test of the Space Segment during SSIOT, except as indicated in paragraph 2.4. • Classroom training to Purchaser on the Space Segment to familiarize experienced operations personnel with the systems and subsystems, and operations of the Space Segment as specified in paragraph 2.3.3 of this SOW. • The support personnel for SSIOT and GBBF AT activities. • Mission Operations Services from Satellite separation from the Launch Vehicle through completion of SSIOT (except as noted in paragraph 2.4 of this SOW). During this period, all Mission Operations shall be performed/controlled from Contractor’s Mission Control Center. • GBBF Subsystem Acceptance Testing as specified in the GBBF Subsystem Acceptance Test Plan, CDRL 28, and the Space Segment Test Procedure document, CDRL 7. • Data as specified in the Contract Data Requirements List (CDRL), Annex 1 attached to this SOW.
Sample 1
BASIC PROGRAM CONTENT a. Four complete communications satellites as shown in Annex 1 in accordance with the Performance Specification (Exhibit B to the Contract) and Product Assurance Plan (Exhibit C to the Contract), and tested in accordance with a Program Test Plan (Exhibit D to the Contract). Four satellites are to be delivered as specified in the Contract.
Sample 1

Related to BASIC PROGRAM CONTENT

  • Marketing Plan The Contractor shall have a Marketing Plan, that has been prior-approved by the SDOH and/or LDSS, that describes the Marketing activities the Contractor will undertake within the local district during the term of this Agreement. The Marketing Plan and all marketing activities must be consistent with the Marketing Guidelines which are set forth in Appendix D, which is hereby made a part of this Agreement as if set forth fully herein. The Marketing Plan shall be kept on file in the offices of the Contractor, LDSS, and the SDOH. The Marketing Plan may be modified by the Contractor subject to prior written approval by the SDOH and/or the LDSS. The LDSS or SDOH must take action on the changes submitted within sixty (60) calendar days of submission or the Contractor may deem the changes approved.

  • Data Processing System, Program and Information (a) The Investment Company shall not, solely by virtue of this Agreement, obtain any rights, title and interest in and to the computer systems and programs, including all related documentation, employed by FTIS in connection with rendering services hereunder; provided however, that the records prepared, maintained and preserved by FTIS pursuant to this Agreement shall be the property of the Investment Company.

  • Marketing Plans 1. The MCO shall develop a marketing plan that meets SDOH guidelines and any local requirements as approved by the State Department of Health (SDOH).

  • Research Plan The Parties recognize that the Research Plan describes the collaborative research and development activities they will undertake and that interim research goals set forth in the Research Plan are good faith guidelines. Should events occur that require modification of these goals, then by mutual agreement the Parties can modify them through an amendment, according to Paragraph 13.6.

  • Development Plans 4.3.1 For each Licensed Indication and corresponding Licensed Product in the Field, Licensee will prepare and deliver to Licensor a development plan and budget (each a “Development Plan”). The initial Development Plans for each Licensed Indication will be delivered within […***…] after the Grant Date for such Licensed Indication.

  • Clinical Data and Regulatory Compliance The preclinical tests and clinical trials conducted by the Company, and to the knowledge of the Company, the preclinical tests and clinical trials conducted on behalf of or sponsored by the Company, that are described in, or the results of which are referred to in, the Registration Statement, the Time of Sale Prospectus or the Prospectus were and, if still pending, are being conducted in all material respects in accordance with the protocols, procedures and controls designed and approved for such studies and with standard medical and scientific research procedures and all applicable laws and regulations, including, without limitation, 21 C.F.R. Parts 50, 54, 56, 58, and 312; each description of the results of such studies is accurate and complete in all material respects and fairly presents the data derived from such studies, and the Company and its subsidiaries have no knowledge of any other studies the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement, the Time of Sale Prospectuses or the Prospectus; the Company and its subsidiaries have made all such filings and obtained all such Permits as may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board (collectively, the “Regulatory Agencies”) for the operation of the Company’s business as currently conducted, except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; neither the Company nor any of its subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or modification of any clinical trials that are described or referred to in the Registration Statement, the Time of Sale Prospectus or the Prospectus; and the Company and its subsidiaries have each operated and currently are in compliance in all material respects with all applicable rules and regulations of the Regulatory Agencies except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

  • Development Work Do, or cause to be done, such development and other work as may be reasonably necessary to protect from diminution and production capacity of the Mortgaged Property and each producing well thereon.

  • Development Plan As defined in Section 3.2(a).

  • Commercialization Reports After the First Commercial Sale of a Licensed Product anywhere in the Territory, LICENSEE shall submit to Cornell semi-annual reports on or before each February 28 and August 31 of each year. Each report shall cover LICENSEE’s (and each Affiliate’s and Sublicensee’s) most recently completed calendar half-year and shall show:

  • Development Activities NovaDel shall not be required to commence any Development Activities until Licensee has paid at least twenty-five percent (25%) of the non-refundable License Fee described in Section 4.4.

Time is Money Join Law Insider Premium to draft better contracts faster.